大行評級|摩根大通:上調創科實業目標價至138港元 2024財年業績表現強勁
摩根大通發表報告指,創科實業2024財年業績表現強勁,亮點包括Milwaukee強勁的銷售增長、毛利率擴張、創紀錄的自由現金流、派息增加。在公司在3月4日收市後公佈財報後,該行更新了對其財務模型,將目標價由今年12月的135港元,上調至明年12月的138港元,並維持“增持”評級。
報告指,創科去年下半年穩健的利潤被較高的利息成本輕微抵消。隨着公司加速去槓桿化,至2024年底淨負債率降至0.7%,成爲2025年的積極因素。管理層業績電話會議關注點包括2025年增長指引、關稅影響應對、持續創新與效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.